Salvatore Privitera sold $271k of ATRC
Chief Technical Officer at AtriCure, Inc.. 4,519 shares at an average of $60.00, traded Sep 23, 2026, filed Sep 24, 2026.
Score components
- +15RoleOfficer
- +13Trade size$271k at market
- 0Share of holdings soldSold 3.1% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001336063-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | SOpen-market sale Common Stock10b5-1 | -4,519 | $60.00 | $271k | 142,745 | 20 d ago |
Related signals
Other insiders at AtriCure, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | AtriCure, Inc. | Regina E Groves director | $288k 5,313 shares | -13% | |
| 15Weak | AtriCure, Inc. | Salvatore Privitera Chief Technical Officer | $201k 3,657 shares | -2% | |
| 26Weak | AtriCure, Inc. | Salvatore Privitera Chief Technical Officer | $408k 7,763 shares | -5% | |
| 40Moderate | AtriCure, Inc. | Karl S. Dahlquist Chief Legal Officer | $458k 9,370 shares | -10% | |
| 46Moderate | AtriCure, Inc. | Karen Prange director | $138k 3,564 shares | -14% | |
| 46Moderate | AtriCure, Inc. | Maggie Yuen director | $134k 3,500 shares | -20% | |
| 49Moderate | AtriCure, Inc. | Sven Wehrwein director | $946k 25,000 shares | -38% | |
| 43Moderate | AtriCure, Inc. | Justin J Noznesky Chief Mktg & Strategy Officer | $240k 6,182 shares | -6% | |
| 43Moderate | AtriCure, Inc. | Vinayak Doraiswamy Chief Scientific Officer | $233k 6,000 shares | -6% | |
| 37Weak | AtriCure, Inc. | Karen Prange director | $86k 3,000 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.